EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Innoviva's enterprise value is $1,228.4 Mil.
Innoviva's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $311.6 Mil. Therefore, Innoviva's EV-to-Revenue for today is 3.94.
The historical rank and industry rank for Innoviva's EV-to-Revenue or its related term are showing as below:
INVA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -27.66 Med: 6.76 Max: 1849.48
Current: 3.96
During the past 13 years, the highest EV-to-Revenue of Innoviva was 1849.48. The lowest was -27.66. And the median was 6.76.
INVA's EV-to-Revenue is ranked better than 67.66% of 1036
companies
in the Biotechnology industry
Industry Median: 8.285
vs INVA: 3.96
As of today (2024-05-10), Innoviva's stock price is $15.285.
Innoviva's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $3.95. Therefore, Innoviva's PS Ratio for today is 3.87.
Innoviva EV-to-Revenue Historical Data
The historical data trend for Innoviva's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innoviva's EV-to-Revenue
For the Biotechnology subindustry, Innoviva's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innoviva's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innoviva's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Innoviva's EV-to-Revenue falls into.
Innoviva's current Enterprise Value is $1,228.4 Mil.
Innoviva's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $311.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva's share price for today is $15.285.
Innoviva's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.95.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Innoviva's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INVA has been successfully added to your 